Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Accured Expenses (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Change in Accured Expenses for 12 consecutive years, with -$115000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 7.48% year-over-year to -$115000.0, compared with a TTM value of $244000.0 through Sep 2025, up 119.49%, and an annual FY2024 reading of -$303000.0, up 41.95% over the prior year.
  • Change in Accured Expenses was -$115000.0 for Q3 2025 at Arcadia Biosciences, down from $156000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $971000.0 in Q3 2021 and bottomed at -$1.3 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$75722.2, with a median of -$54500.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 10400.0% in 2022, while the deepest fall reached 6700.0% in 2022.
  • Year by year, Change in Accured Expenses stood at -$1.3 million in 2021, then skyrocketed by 166.67% to $896000.0 in 2022, then plummeted by 159.49% to -$533000.0 in 2023, then surged by 178.05% to $416000.0 in 2024, then crashed by 127.64% to -$115000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for RKDA at -$115000.0 in Q3 2025, $156000.0 in Q2 2025, and -$213000.0 in Q1 2025.